Role of Pharma Companies in the AI-enabled Drug Discovery Landscape

So far in our blog series on Artificial Intelligence in Drug Discovery (AIDD), we looked at active AIDD clusters across the globe, the key techniques used for drug discovery (Part 1 & Part 2), and how various companies are shaping the ecosystem. In this blog, we take a closer look at the role of pharmaceutical […]

Four Weeks In: 12 Week ALS Drug Discovery Challenge

You may have seen that we have embarked on a 12 week challenge with our partner GenieUs Genomics to make a highly focused and concentrated effort towards finding new, efficient and safe treatment options for a nervous system disease, Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive, degenerative disease that destroys the nerve cells that […]

Ensuring reproducibility in biomedical research

Data and metadata are the foundation of reproducible biomedical research. Wet lab researchers, funding bodies and research managers often struggle, however, to find robust solutions for implementing smart data stewardship — collecting not only bare-minimum results data but also valuable ancillary information, including experimental process data and measurements, commonly referred to as metadata. Collecting such […]

Which companies are shaping the AI drug discovery industry at the moment?

The need to rethink the way we approach the discovery and development of new drugs has become more and more clear over the past two decades. In our previous blog post, we discussed the enormous cost and effort needed to discover new drugs and how AI and automation can help reduce them. This potential has […]

Driving the evolution of AI-enabled drug discovery – a global perspective

We often receive questions about global trends in Artificial Intelligence (AI) for drug discovery. Over the coming months, we will explore  these questions in a series of blogs. Today, we address one of the most frequently asked questions: which geographies are driving the evolution of AI drug discovery first and foremost and what are predictions […]

How AI & Automation help Target Identification & Validation in Drug Discovery


An Intelligent OMICS & Arctoris Partnership The ability of Artificial Intelligence (AI) to transform drug discovery is widely seen as one of the biggest disruptors within the biotech and pharma industry. Our partnership with Intelligent OMICS demonstrates a powerful example of how AI and automation enable faster and better target identification and validation for drug […]

Why Should Early-Stage Biotechs Care about Intellectual Property?


Hester Sheehan, Research Scientist at Arctoris, reflects on her IP journey on World Intellectual Property Day. April 26th is World Intellectual Property Day and as someone about to embark on a career in this field, I thought this would be a timely opportunity to discuss my thoughts on the importance of intellectual property (IP) for early-stage […]

Early-Stage Drug Discovery and the Importance of High-Quality Data

Goodwin-Arctoris Drug Discovery Masterclass Recap Professionals in drug discovery and development face difficult odds: on average, it takes 12 to 15 years to take a new drug from the idea stage to market approval; that is around one-third of a scientist’s professional life! The costs are eye-watering as well: the price tag of taking a […]